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Abstract 
Background 
In a malignant tumour, cancer cells are embedded in stromal cells, namely cancer-associated 
fibroblasts (CAFs). These CAFs are now accepted as important players in cancer dynamics, 
being involved in tumour growth and progression. Although there are various reports on the 
interaction between tumour and stromal cells, the clinico-pathological significance of this 
cross-talk is still largely unknown. In this study, we aimed to characterise the expression of 
key metabolic proteins involved in glucose transport, pyruvate/lactate shuttle system, 
glycolytic metabolism and fatty acid oxidation in CAFs and tumour cells in different stages 
of malignant transformation. We further aimed to contextualise the clinico-pathological 
significance of these protein expression profiles with reference to known prognostic 
indicators, including biochemical recurrence in pT stage. 
Methods 
Prostate tissues were obtained from 480 patients with a median age of 64 years following 
radical prostatectomy with no previous hormonal therapy. Tissues were analysed for the 
expression of several key metabolism-related proteins in glands and surrounding fibroblasts 
by immunohistochemistry. Reliable markers of prognosis such as pT stage and biochemical 
recurrence were assessed for each case. 
Results 
We observed that prostate cancer cells did not rely mainly on glycolytic metabolism, while 
there was a high expression of MCT4 and CAIX - in CAFs. This corroborates the hypothesis 
of the “Reverse Warburg effect” in prostate cancer, in which fibroblasts are under oxidative 
stress and express CAIX, an established hypoxia marker. We found that alterations in the 
expression of metabolism-related proteins were already evident in the early stages of 
malignant transformation, suggesting the continuing alteration of CAFs from an early stage. 
Additionally, and for the first time, we show that cases showing high MCT4 expression in 
CAFs with concomitant strong MCT1 expression in prostate cancer (PCa) cells are associated 
with poor clinical outcome, namely pT3 stage of the tumour. 
Conclusions 
In summary, this work demonstrates for the first time the clinico-pathological significance of 
the lactate shuttle in prostate cancer. It also suggests that other alterations in CAFs may be 
useful prognostic factors, and further supports the use of MCT1/MCT4 as targets for PCa 
therapy. 
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Background 
It is well established that solid tumours, including prostate cancer, exist under fluctuating 
oxygen tension, during which they are intermittently exposed to hypoxia [1,2]. Under 
hypoxic conditions, tumour cells primarily use glycolysis for energy, producing lactate, 
which is expelled to the tumour microenvironment, allowing tumours to continue their 
glycolytic activity [3,4]. Recently, Sonveaux et al. showed that lactate, which is generally 
considered a waste product, is preferred over glucose by oxidative tumour cells as their 
primary energy source [5]. 
Monocarboxylate transporters (MCTs) have been shown to play an important role in various 
tumours [6]. However, since they facilitate the transport of lactate in and out of cells, their 
role in this stromal/epithelial cell symbiosis is also attracting interest. MCT1 is a high-affinity 
transporter and its expression seems to be regulated by multiple signalling pathways, micro-
environmental parameters, changes in substrate concentration and pH [7]. MCT4 is a low-
affinity transporter, which is abundant in highly glycolytic muscle cells and is one of the 
many target genes of hypoxia-inducible factor 1 alpha (HIF-1α) [8]. Other targets of HIF-1α 
include glucose transporter-1 (GLUT-1), the main transporter involved in glucose uptake 
[9,10]; lactate dehydrogenase V (LDHV), which is responsible for the conversion of pyruvate 
into lactate; pyruvate dehydrogenase kinase isozyme 1 (PDK1), which is responsible for the 
phosphorylation and consequent inactivation of pyruvate dehydrogenase (PDH); and carbonic 
anhydrase IX (CAIX), a hypoxia-related protein involved in pH regulation [11]. Alpha-
methylacyl-CoA racemase (AMACR), pristanoyl-CoA oxidase (ACOX-3) and D-
bifunctional protein (DBP), are also important fatty acid oxidation-related proteins in prostate 
cancer [12,13], and we also included them in our analysis. 
The importance of a lactate shuttle system between cancer cells and surrounding stroma has 
been described in various tumour types [14-16], but its significance in prostate cancer is not 
clear [17,18]. 
In this study, we aimed to identify a metabolic interaction between CAFs and prostate cancer 
cells, by analysing the expression of key metabolism-related proteins in CAFs in relation to 
prostate cancer using prostate tissue samples. We also assessed the clinico-pathological 
significance of this expression to investigate a possible CAF signature for PCa progression. 
Methods 
Patient sample selection 
Formalin–fixed paraffin embedded tissues from 480 prostate cancer patients were retrieved 
from the archives of the Department of Pathology of Centro Hospitalar do Porto, Portugal. 
Stroma surrounding non-neoplastic glands, prostatic intra-epithelial hyperplasia (PIN) lesions 
and malignant glands were also analysed. Prostate cancer patients were selected for the study 
according to the following criteria: availability of both tumour and normal tissue for each 
patient, presence of adequate amount of stroma in both normal and tumour tissues for 
efficient selection for tissue microarray construction (TMA), and absence of chemotherapy or 
radiotherapy. Prior to TMA construction, tissue morphology was assessed on HE slides. Data 
for clinical parameters significant in patient outcome were available, including pre-operative 
serum total PSA, clinical stage, perineural invasion and biochemical recurrence. 
Ethics 
The work has been approved by DEFI (Departamento de Ensino Formação e Investigação) 
Ethics Committee of Centro Hospitalar do Porto ref. no. 017/08(010-DEFI/015-CES). 
Immunohistochemistry 
Samples organised into TMAs including 203 non-neoplastic, 176 PIN and 480 neoplastic 
tissues were analysed for MCT1, MCT4, GLUT-1, GLUT-12, LDHV, PDK1, CAIX, 
AMACR, ACOX-3 and DBP expression. Staining was evaluated using a combined score 
system, as previously described [19]. Detailed information regarding the 
immunohistochemistry (IHC) technique is given in Table 1. 
Table 1 Details of the immunohistochemical procedure used to analyze the expression of 
the different proteins 
Protein Antibody Company Antibody 
dilution 
Positive 
control 
Incubation 
period 
Detection system 
MCT4 sc-50329 Santa Cruz 
Biotechnology 
1:500 Colon 
tumor 
Overnight R.T.U. Vectastain 
Universal Elite ABC Kit, 
Vector, EUA 
GLUT1 ab 15309 Abcam 1:2000 Head and 
neck 
tumor 
2 hours Ultravision Detection 
System Anti-polyvalent, 
HRP, Labvision 
Corporation, Freemont, CA CAIX ab 15086 Abcam 1:2000 Stomach 
MCT1 sc-365501 Santa Cruz 
Biotechnology 
1:500 Colon 
tumor 
Overnight R.T.U. Vectastain 
Universal Elite ABC Kit, 
Vector, EUA 
GLUT12 ab 75441 Abcam 1:500 Rim Overnight  
LDHV ab 53010 Abcam 1:1000 Colon 
tumor 
2 hours Ultravision Detection 
System Anti-polyvalent, 
HRP, Labvision 
Corporation, Freemont, CA 
PDK1 ab 110025 Abcam 1:500 Stomach 
AMACR 504R-16 Cell Marque 1:50 Kidney 
ACOX3 sc-135435 Santa Cruz 
Biotechnology 
1:250 Liver 
DBP DBP antibody was a gift from Dr. 
Gabriele Moller from 
HelmholtzZentrum mÜnchen. 
Ready to 
use 
Kidney 
Immunohistochemical evaluation 
IHC evaluation was performed as previously described [19] and scored independently by two 
pathologists (JRV, CL), blinded to the target under study. For statistical purposes, only 
moderate and strong immunoreaction final scores were considered positive. Discordant cases 
were discussed in order to agree on a final score. 
Statistics 
Statistical analysis was performed using the SPSS statistical software (version 17.0, SPSS 
Inc., Chicago, IL, USA). All comparisons were examined for statistical significance using 
Pearson’s chisquare (χ2) test, using a threshold for significance of p < 0.05. Figure 1 was 
generated in part using R statistical computing environment, R version 3.0.0 [20] The code 
for the aesthetics of the stacked bar graphs was originally written by Kim Herzig [21]. 
Figure 1 Stacked bar graph according to one protein column within each fibroblast 
group for MCT4, PDK1 and CAIX expression. The stronger expression (3) is represented 
by the more intense colour. 
Results 
We observed obvious differences between the expression of key metabolism-related proteins 
in CAFs and tumour cells (Figure 2). MCT1, MCT4, LDHV, PDK1, GLUT-1, GLUT-12, 
CAIX, AMACR, ACOX-3 and DBP were differentially expressed between stromal and 
epithelial cells, while MCT1, LDHV, GLUT-1, GLUT-12, AMACR, ACOX-3 and DBP 
were exclusively expressed in prostate cancer cells. MCT4 and CAIX were expressed more 
strongly in CAFs, and PDK1 stained both malignant glands and CAFs. 
Figure 2 Comparison between metabolism-related proteins expression in tumour cells 
and cancer associated fibroblasts (CAFs). 
Additionally, we assessed whether fibroblasts exhibited differences in protein expression 
across different stages of malignant transformation by analysing the expression of the same 
proteins in fibroblasts surrounding benign glands (benign-associated fibroblasts; BAFs), PIN-
associated fibroblasts (PAFs) and CAFs. Figure 1 shows stacked bar graphs representing the 
expression of MCT4, PDK1 and CAIX in more detail, since these proteins were the ones 
exhibiting a clear expression in fibroblasts surrounding both benign and malignant glands. A 
statistically significant increase in both MCT4 and PDK1 expression in CAFs compared to 
BAFs was observed (both p < 0.001). Curiously, CAIX was also observed in fibroblasts 
surrounding non-neoplastic glands (benign glands and PIN lesions) (see also Figure 3). 
Figure 3 Immunohistochemical staining for MCT1, MCT4, PDK1 and CAIX expression 
in non-neoplastic tissue (NNT), PIN lesions (PIN), tumour tissue (TT) and the 
surrounding stroma for each case. Strong expression of MCT4, PDK1 and CAIX in 
stromal cells is evident, in contrast with MCT1, which is present only in the epithelial cells of 
the glands. 
Key metabolism-related proteins in fibroblasts and prostate glands across malignant 
transformation, i.e. from BAFs to PAFs and finally CAFs, were investigated. MCT1 was 
clearly expressed in the plasma membrane of prostate glands, but not the surrounding stroma. 
In contrast, the expression of MCT4 increased in fibroblasts with increasing degree of 
malignant transformation, but not in the prostate glands. PDK1 expression was detected in 
both glands and stroma, whereas CAIX was only detected in stroma, with no staining in 
prostate glands (Figure 3). 
Associations between the expression of the metabolic proteins and clinico-pathological data 
are presented in Table 2. We observed that CAIX expression in CAFs was associated with 
biochemical recurrence after surgery (p = 0.003). Furthermore, the strongest associations 
identified were in samples with elevated levels of MCT1 in tumour cells together with 
elevated levels of MCT4 in the surrounding CAFs. These cases were associated with pT3 
tumour stage (p = 0.009). Additionally, cases negative for both MCT1 and MCT4, or positive 
for MCT1 in the malignant glands and negative for MCT4 in CAFs, showed no associations 
with clinico-pathological parameters (data not shown). 
Table 2 Correlations between the key metabolic-related proteins MCT4, PDK1 and 
CAIX expressions in CAFs and clinico-pathological data 
  MCT4 PDK1 CAIX MCT1/MCT4* 
Variable n % p % p % p % p 
PSA (ng/ml)   0.296  0.451  0.250  0.525 
≤ 5.0 245 47.9  16.2  85.9  27.1  
>5.0 123 44.0  17.5  82.2  27.5  
pT   0.445  0.258  0.522  0.009 
2 359 40.2  18.7  86.4  20.8  
3 99 41.7  15.2  86.9  33.3  
Perineural          
Invasion   0.155  0.069  0.399  0.255 
Absent 119 45.4  13.4  85.8  26.9  
Present 327 39.4  19.8  87.2  23.3  
Biochemical          
Recurrence   0.104  0.176  0.003  0.052 
Absent 410 40.2  18.5  75.4  22.6  
Present 69 49.3  13.0  89.0  32.8  
The correlation between MCT1/MCT4 expression (*MCT1 expression in prostate tumour 
cells with concomitant expression of MCT4 in CAFs) and the clinico-pathological data is 
also presented. 
Discussion 
Several research groups have recently focused on the role of CAFs in the progression and 
metastasis of prostate cancer, showing that a dynamic interaction between stroma and 
epithelium might play a critical role in this progression [14,15,22-25]. Thus, the essential role 
played by the cross-talk between stroma and epithelium in carcinogenesis and prostate cancer 
progression has been increasingly recognised. In this work, we provide evidence for the 
possible metabolic co-operation between cancer cells and the surrounding fibroblasts by 
examining the expression of major proteins involved in cellular metabolism. In particular, we 
focus on differences between cancer cells and tumour-associated fibroblasts, as well as 
between fibroblasts in different stages of malignant transformation, and examine the possible 
clinico-pathological significance of the expression of these proteins. 
By categorising the protein expression of stromal cells associated with prostate cancer, we 
describe a compartment that is not well studied and will contribute to an improved 
understanding of prostate cancer. We observed significant differences between CAFs and 
tumour glands with respect to the expression of key metabolic proteins. In particular, CAIX 
and MCT4 selectively labelled cancer associated fibroblasts in contrast to malignant glands, 
where CAIX and MCT4 were only present in very few cases. On the other hand, a distinct, 
strong membranous expression of MCT1 was consistently observed in cancer cells, 
suggesting a role for MCT1 in the transport of lactate into tumour cells from the acidic 
extracellular matrix, suggesting that lactate might be used as a fuel by oxidative cancer cells. 
We also observed that proteins involved in fatty acid oxidation, such as AMACR, ACOX-3 
and DBP, were restricted to the tumour cells, which is consistent with the presence of a 
metabolic pathway different from glycolysis, and compatible with oxidative phosphorylation 
in prostate cancer cells. It is important to note that fatty acid oxidation is already considered a 
major source of acetyl-CoA for the Krebs cycle [13], which further supports our hypothesis. 
The expression levels of GLUT1, a key glucose transporter, define the rates of glucose influx 
into the cells. In the present study, CAFs did not show GLUT1 or GLUT-12 expression, and 
LDHV was also difficult to detect. However, this possibly reflects the limits of the 
immunohistochemical technique to detect these proteins at the baseline concentrations 
present in CAFs. Indeed, we have previously found very few cases positive for GLUT-1 and 
GLUT-12, and this expression was not present at the plasma membrane, suggesting a low 
level of activity of these proteins in prostate cancer cells (unpublished results). Thus, 
assessment of other GLUT isoforms may be worthwhile. 
Interestingly, we also observed that protein expression of MCT4, PDK1 and CAIX in 
prostate fibroblasts changes during malignant transformation, suggesting that the existing 
stroma might also suffer alterations and play a role in this metabolic adaptation of cancer 
cells beyond the well-studied role of newly formed stroma. 
From the above immunohistochemical findings, it seems that well-organised metabolic 
regions composed of tumour cells and CAFs may contribute to the ability of the tumour to 
overcome the adverse microenvironment. 
Our hypothesis is in agreement with those of Fiaschi et al. [17], who describe the metabolic 
reprogramming of CAFs towards the Warburg phenotype as a result of contact with prostate 
cancer cells. Using in vitro studies, they showed lactate production and efflux by de novo 
expressed MCT4 in CAFs and also demonstrated that, upon contact with CAFs, prostate 
cancer cells were reprogrammed towards aerobic metabolism, with an increase in lactate 
uptake via the lactate transporter MCT1. Furthermore, pharmacological inhibition of MCT1-
mediated lactate uptake dramatically affected PCa cell survival and tumour outgrowth. 
However, in this study, no data regarding clinico-pathological associations were shown, and 
few cases were assessed. These findings are in contrast with others ([18], which describe an 
energy recycling path between the aerobic stroma and the anaerobic cancer cells within the 
framework of the Warburg effect. These conclusions are based mainly on the observation that 
LDH1 is evidently expressed in CAFs, and the presence of MCT1 in prostate cancer cells was 
attributed to its role in lactate efflux and not its uptake. We recognise the importance of 
assessing LDH1; however, in our study we assessed for the first time MCT4 and CAIX as 
important markers of hypoxia in a larger cohort. Our findings corroborate the work of 
Whitaker-Menezes et al. [16], who described a “reverse Warburg effect,” where CAFs 
undergo aerobic glycolysis to produce lactate, which is subsequently used as a metabolic 
substrate by adjacent cancer cells. In this model, “energy transfer” or “metabolic coupling” 
between the tumour stroma and epithelial cancer cells fuels tumour growth and metastasis via 
oxidative mitochondrial metabolism in anabolic cancer cells. We believe that this is also the 
case in prostate cancer, although more studies are needed to demonstrate this. 
Also, we assessed important clinico-pathological parameters and found significant 
associations with poor prognosis, raising once more the possible role of CAFs in disease 
management. We believe that these changes are likely to be a by-product of tumour biology 
with further influence on patient outcomes that need to be explored more deeply. 
In summary, we found differences between prostate cancer cells and CAFs using tissues from 
480 patients, showing elevated expression of MCT4 and CAIX in CAFs and demonstrating 
for the first time that the concomitant expression of MCT1 in tumour cells and MCT4 in 
fibroblasts in the same tissue is clinically significant, and associated with poor prognosis. 
Indeed, the stromal expression of hypoxia-regulated proteins appears to be prognostic of poor 
outcome in prostate carcinomas, suggesting that tumour hypoxia may influence tumour-
associated stromal cells in a way that ultimately contributes to patient outcome. Figure 4 
shows a schematic representation of the lactate shuttle between CAFs and PCa cells to 
illustrate the hypothesis presented in our work. 
Figure 4 Schematic representation of the lactate shuttle system between malignant cells 
and cancer associated fibroblasts (CAFs). The expression of MCT4 in CAFs together with 
the expression of MCT1 in tumour cells is associated with biochemical recurrence after 
surgery and pT3 stage of the tumour. 
Conclusions 
In summary, we show for the first time that there is a clinico-pathological significance for the 
MCT1/MCT4 lactate shuttle in prostate cancer. In fact, it seems that the stromal expression of 
hypoxia-regulated proteins is an adverse prognostic factor in prostate carcinomas, suggesting 
that tumour hypoxia may influence tumour-associated stromal cells in a way that ultimately 
contributes to patient prognosis. 
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